Rosalind P. Candelaria, M.D.

Peer-Reviewed Articles

1. Wanis KN, Krasniqi R, Sun SX, Resetkova E, Hwang RF, Hunt KK, Candelaria RP, Huo L, Singh P. Sentinel Lymph Node Positivity and Utility of Frozen Section Diagnosis following Neoadjuvant Therapy in Patients with Clinically Node-Negative, Hormone Receptor-Positive, HER2-Negative Breast Cancer. Ann Surg Oncol 33(8):7237-7243, 2026. e-Pub 2026. PMID: 42135547.
2. Pan X, Ercan C, Wang, Bassett RL, Gonzales KBP, Rauch GM, Adrada BE, Candelaria RP, Tripathy D, Litton JK, Giordano SH, Valero V, Arun B, Clayborn A, Virani K, White J, Ding Q, Sahin AA, Symmans WF, Yam C, Huo L, Yuan Y. AI-derived tumor-infiltrating lymphocytes enhance the prediction of pathologic complete response in early-stage triplenegative breast cancer. NPJ Breast Cancer. e-Pub 2026.
3. Wanis, K, Krasniqi, R, Sun, SX, Resetkova, E, Hwang, RF, Hunt, KK, Candelaria, RP, Huo, L, Singh, P. ASO Visual Abstract:Sentinel Lymph Node Positivity and Utility of Frozen Section Diagnosis After Neoadjuvant Therapy for Patients with Clinically Node-Negative Hormone Receptor-Positive, HER2-Negative Breast Cancer 33(8):7260-7261, 2026. e-Pub 2026. PMID: 42189440.
4. Lee, KL, Yam, C, Zhao, L, Bassett Jr, R, Song, X, Thompson, A, White, JB, Layman, RM, Huo, L, Gutierrez, AM, Valero, V, Ueno, NT, Litton, J, Zhang, J, Ravenberg, EE, Korkut, A, Adrada, BE, Candelaria, RP, Rauch, GM, Tripathy, D, Shaitelman, SF, Arun, BK. Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial. Breast Cancer Res Treat 217(2), 2026. e-Pub 2026. PMID: 42223695.
5. Huo, X, Moseley, T, Adrada, BE, Yam, C, Huo, L, Guirguis, MS, Patel, MM, Leung, J, Whitman, GJ, Candelaria, RP, Lane, DL, Yang, WT, Sun, J, Litton, J, Valero, V, Arun, BK, Hwang, K, Wei, P, Ma, J, Rauch, GM. DCE-MRI for assessment of pathologic complete response after completion of neoadjuvant therapy in triple-negative breast cancer patients. Journal of Clinical Oncology 44:611, 2026. e-Pub 2026.
6. Weaver OO, Contreras A, Cohen EO, Guirguis MS, Kapoor MM, Scoggins ME, Hwang RF, Candelaria RP, Yang WT, Dennison JB, Sun J, Whitman GJ. Assessment of Pectoralis muscle invasion using combined DBT and contrast-enhanced mammography: Retrospective multi-reader study. Curr Probl Diagn Radiol 55(1):95-104, 2026. e-Pub 2026. PMID: 40288929.
7. Adrada, BE, Guirguis, MS, Huo, L, Yam, C, Tripathy, D, Candelaria, RP, Yang, W, Patel, MM, Moseley, T, Whitman, GJ, Leung, J, Le-Petross, H, Lane, DL, Abuhadra, NK, Litton, J, Valero, V, Hunt, KK, Arun, BK, Mohamed, R, Sun, J, Korkut, A, Pashapoor, S, White, JB, Thompson, A, Wei, P, Ma, J, Moulder, S, Rauch, GM. Imaging- and Tumor Biomarker–Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 41411609.
8. Guirguis M, Adrada B, Yam C, Tripathy D, Candelaria RP, Yang W, Patel M, Moseley T, Perez F, Whitman G, Leung J, Le-Petross H, Lane D, Huo L, Litton J, Valero V, Hunt K, Arun B, Mohamed R, Sun J, Korkut A, Xu Z, Pashapoor S, White J, Son J, Thompson A, Wei P, Ma J, Moulder S, Rauch G. Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer. NPJ Breast Cancer 11(1):129, 2025. e-Pub 2025. PMID: 41266347.
9. Rauch GM, Adrada BE, Guirguis MS, Huo L, Yam C, Tripathy D, Candelaria RP, Yang W, Patel M, Moseley T, Whitman GJ, Leung JWT, Le-Petross H, Lane DL, Abuhadra N, Litton J, Valero V, Hunt KK, Arun B, Mohamed R, Sun J, Korkut A, Pashapoor S, White J, Thompson A, Wei P, Ma J, Moulder S. Multivariable Model for Early Prediction of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer Receiving Neoadjuvant Systemic Therapy. JCO Precision Oncology. e-Pub 2025.
10. Kuerer, HM, Valero, V, Smith, BD, Krishnamurthy, S, Diego, EJ, Johnson, HM, Lin, Y, Shen, Y, Lucci, A, Shaitelman, SF, Mitchell, MP, Boughey, JC, White, RL, Hunt, KK, Yang, WT, Rauch, GM, Moseley, T, Leung, J, Huang, ML, Candelaria, RP, Adrada, BE, Arribas, E, van la Parra, RF, Ramirez, DL, Teshome, M, Hwang, RF, Miggins, MV, Piotrowski, MJ, Correa Refinetti, AP, Ehlers II, RA, Mouabbi, JA, Colen, JS, Loveland-Jones, C, Lesnikowski, BA, Samiian, L, Chong, C, Black, DM, Desyder, SM, Sun, SX, Nguyen, TM. Selective Elimination of Breast Surgery for Invasive Breast Cancer A Nonrandomized Clinical Trial. JAMA Oncology 11(5):529-534, 2025. e-Pub 2025. PMID: 40152443.
11. Xu Z, Zhou Z, Son JB, Feng H, Adrada BE, Moseley TW, Candelaria RP, Guirguis M, Patel MM, Whitman GJ, Leung J WT, Le-Petross HT, Mohamed RM, Panthi B, Lane DL, Chen H, Wei P, Tripathy D, Litton JK, Valero V, Huo L, Hunt KK, Korkut A, Thompson A, Yang W, Yam C, Rauch GM, Ma J. Deep learning models based on pretreatment MRI and clinicopathological data to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Cancers 17(6), 2025. e-Pub 2025. PMID: 40149299.
12. Huang ML, Lane DL, Chang Sen LQ, Candelaria RP, Kuerer HM, Hunt KK, Akay C, Lim B, Shaitelman S, Hwang RF, Chen H, Katta R, Santiago L. Defining breast cryoablation treatment success: a guide for the curative and palliative treatment of breast cancer. Acad Radiol 31(12):4759-4771, 2024. e-Pub 2024. PMID: 39107186.
13. Wanis KN, Goetz L, So A, Glencer AC, Sun SX, Teshome M, Resetkova E, Hwang RF, Hunt KK, Candelaria RP, Huo L, Singh P. The prevalence of sentinel lymph node positivity and implications for the utility of frozen section diagnosis following neoadjuvant systemic therapy in patients with clinically node-negative HER2-positive or triple-negative breast cancer. Ann Surg Oncol 31(11):7339-7346, 2024. e-Pub 2024. PMID: 39048903.
14. Yam, C, Patel, MM, Hill, H, Sun, R, Bassett Jr, R, Kong, EK, Damodaran, S, Koenig, KB, Abouharb, S, Saleem, S, Bisen, AK, Murthy, RK, Ramirez, DL, Rauch, GM, Adrada, BE, Candelaria, RP, Wang, X, Mittendorf, EA, Thompson, A, White, JB, Ravenberg, EE, Clayborn, A, Ding, Q, Booser, DJ, Oke, OC, Brewster, A, Hortobagyi, GN, Ibrahim, NK, Litton, J, Valero, V, Arun, BK, Tripathy, D, Chang, J, Chen, K, Korkut, A, Moulder, S, Huo, L, Lim, B, Ueno, NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Research Communications 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
15. Mohamed, RM, Panthi, B, Adrada, BE, Boge, M, Candelaria, RP, Chen, H, Guirguis, MS, Hunt, KK, Huo, L, Hwang, K, Korkut, A, Litton, JK, Moseley, T, Pashapoor, S, Patel, MM, Reed, BJ, Scoggins, ME, Son, JB, Thompson, A, Tripathy, D, Valero, V, Wei, P, White, JB, Whitman, GJ, Xu, Z, Yang, W, Yam, C, Ma, J, Rauch, GM. Multiparametric MRI–based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 38992094.
16. Lim B, Seth S, Yam C, Huo L, Fujii T, Candelaria R, Lee J. “Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor–enriched TNBC: trial results and insights into “ARness”. Cell Rep Med 5(6), 2024. e-Pub 2024. PMID: 38838676.
17. Lim, B, Seth, S, Yam, C, Huo, L, Fujii, T, Lee, J, Bassett Jr, R, Nasser, S, Ravenberg, L, White, JB, Clayborn, A, Guerra, G, Litton, J, Damodaran, S, Layman, RM, Valero, V, Tripathy, D, Lewis, MT, Dobrolecki, LE, Lei, JT, Candelaria, RP, Arun, BK, Rauch, GM, Zhao, L, Zhang, J, Ding, Q, Symmans, WF, Chang, J, Thompson, A, Moulder, S, Ueno, NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC. Cell Reports Medicine 5(6), 2024. e-Pub 2024. PMID: 38838676.
18. Musall BC, Rauch DE, Mohamed RMM, Panthi B, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed BJ, Scoggins ME, Son JB, Tripathy D, Valero V, Wei P, White JB, Whitman GJ, Xu Z, Yang WT, Yam C, Adrada BE, Ma J. Diffusion tensor imaging for characterizing changes in triple-negative breast cancer during neoadjuvant systemic therapy. J Magn Reson Imaging 60(4):1367-1376, 2024. e-Pub 2024. PMID: 38294179.
19. Zhou, Z, Adrada, BE, Candelaria, RP, Elshafeey, N, Boge, M, Mohamed, RM, Pashapoor, S, Sun, J, Xu, Z, Panthi, B, Son, JB, Guirguis, MS, Patel, MM, Whitman, GJ, Moseley, T, Scoggins, ME, White, JB, Litton, J, Valero, V, Hunt, KK, Tripathy, D, Yang, WT, Wei, P, Yam, C, Pagel, MD, Rauch, GM, Ma, J. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Scientific reports 13(1), 2023. e-Pub 2023. PMID: 36670144.
20. Nia E, Patel M, Kapoor M, Guirguis M, Perez F, Bassett R, Candelaria R. Comparing the performance of full-field digital mammography and digital breast tomosynthesis in the post treatment surveillance of patients with a history of breast cancer: a retrospective study. Radiography (Lond) 29(6):975-979, 2023. e-Pub 2023. PMID: 37572571.
21. Panthi B, Mohamed RM, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, K-P H, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel M, Chen H, Sun J, Wei P, Thompson AM, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front. Oncol 13, 2023. e-Pub 2023. PMID: 37941561.
22. Xu, Z, Rauch, DE, Mohamed, RM, Pashapoor, S, Zhou, Z, Panthi, B, Son, JB, Hwang, K, Musall, BC, Adrada, BE, Candelaria, RP, Leung, J, Le-Petross, H, Lane, DL, Perez, F, White, JB, Clayborn, A, Reed, BJ, Chen, H, Sun, J, Wei, P, Thompson, A, Korkut, A, Huo, L, Hunt, KK, Litton, J, Valero, V, Tripathy, D, Yang, W, Yam, C, Ma, J. Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer. Cancers 15(19), 2023. e-Pub 2023. PMID: 37835523.
23. Johnson HM, Lin H, Shen Y, Diego EJ, Krishnamurthy S, Yang WT, Smith BD, Valero V, Lucci A, Sun SX, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Rauch GM, Kuerer HM, Moseley TW, Leung JW, Huang M, Candelaria RP, et al. Patient-reported outcomes of omission of breast surgery following neoadjuvant systemic therapy a nonrandomized clinical trial. JAMA Netw Open, 2023. e-Pub 2023. PMID: 37707811.
24. Hwang, K, Elshafeey, N, Kotrotsou, A, Chen, H, Son, JB, Boge, M, Mohamed, RM, Abdelhafez, AH, Adrada, BE, Panthi, B, Sun, J, Musall, BC, Zhang, S, Candelaria, RP, White, JB, Ravenberg, EE, Tripathy, D, Yam, C, Litton, J, Huo, L, Thompson, A, Wei, P, Yang, WT, Pagel, MD, Ma, J, Rauch, GM. A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer. Radiology: Imaging Cancer 5(4), 2023. e-Pub 2023. PMID: 37505106.
25. Abuhadra, NK, Sun, R, Yam, C, Rauch, GM, Ding, Q, Lim, B, Thompson, A, Mittendorf, EA, Adrada, BE, Damodaran, S, Virani, K, White, JB, Ravenberg, EE, Sun, J, Choi, J, Candelaria, RP, Arun, BK, Ueno, NT, Santiago, L, Saleem, S, Abouharb, S, Murthy, RK, Ibrahim, NK, Sahin, AA, Valero, V, Symmans, WF, Litton, J, Tripathy, D, Moulder, S, Huo, L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers 15(13), 2023. e-Pub 2023. PMID: 37444385.
26. Zhou, Z, Adrada, BE, Candelaria, RP, Elshafeey, N, Boge, M, Mohamed, RM, Pashapoor, S, Sun, J, Xu, Z, Panthi, B, Son, JB, Guirguis, MS, Patel, MM, Whitman, GJ, Moseley, T, Scoggins, ME, White, JB, Litton, J, Valero, V, Hunt, KK, Tripathy, D, Yang, W, Wei, P, Yam, C, Pagel, MD, Rauch, GM, Ma, J. Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. Annual International Conference of the IEEE Engineering in Medicine and Biology Society 2023:1-4, 2023. e-Pub 2023. PMID: 38083160.
27. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman R, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder S, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Research and Treatment 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
28. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: A phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
29. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson A, Mittendorf EA, Adrada B, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo\L. Predictive role of baseline stromal tumor-infiltrating lymphocytes and Ki-67 for pathologic complete response in an early-stage triple-negative breast cancer prospective trial. Cancers 15, 2023. e-Pub 2023.
30. Panthi, B, Adrada, BE, Candelaria, RP, Guirguis, MS, Yam, C, Boge, M, Chen, H, Hunt, KK, Huo, L, Hwang, K, Korkut, A, Lane, DL, Le-Petross, H, Leung, J, Litton, J, Mohamed, RM, Musall, BC, Pashapoor, S, Patel, MM, Perez, F, Son, JB, Thompson, A, Valero, V, Wei, P, White, JB, Xu, Z, Pinsky, L, Tripathy, D, Yang, WT, Ma, J, Rauch, GM. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI. Cancers 15(4), 2023. e-Pub 2023. PMID: 36831368.
31. Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White J, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Assessment of response to neoadjuvant systemic treatment in triple-negative breast cancer using functional tumor volumes from longitudinal dynamic contrast-enhanced MRI. Cancers 15(4), 2023. e-Pub 2023.
32. Panthi, B, Mohamed, RM, Adrada, BE, Boge, M, Candelaria, RP, Chen, H, Hunt, KK, Huo, L, Hwang, K, Korkut, A, Lane, DL, Le-Petross, H, Leung, J, Litton, J, Pashapoor, S, Perez, F, Son, JB, Sun, J, Thompson, A, Tripathy, D, Valero, V, Wei, P, White, JB, Xu, Z, Yang, W, Zhou, Z, Yam, C, Rauch, GM, Ma, J. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Frontiers in Oncology 13, 2023. e-Pub 2023. PMID: 37941561.
33. Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, Candelaria R, Santiago L, Adrada BE, Lane DL, Rauch GM, Yang WT, White JB, Chang JT, Moulder SL, Symmans WF, Hilsenbeck SG, Piwnica-Worms H. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer 9(1):2, 2023. e-Pub 2023. PMID: 36627285.
34. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Scientific Reports 13(1171), 2023. e-Pub 2023. PMID: 36670144.
35. Hwang KP, Elshafeey NA, Kotrotsou A, Chen H, Son JB, Boge M, Mohamed RM, Abdelhafez AH, Adrada BE, Panthi B, Sun J, Musall BC, Zhang S, Candelaria RP, White JB, Ravenberg EE, Tripathy D, Yam C, Litton JK, Huo L, Thompson AM, Wei P, Yang WT, Pagel MD, j M, Rauch GM. A radiomics model based on Synthetic MR acquisition for predicting neoadjuvant systemic treatment response in triple-negative breast cancer. Radiology: Imaging Cancer 5(4), 2023. e-Pub 2023.
36. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15:17588359231189422, 2023. e-Pub 2023. PMID: 37547448.
37. Musall BC, Adrada BE, Candelaria RP, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Santiago L, Whitman GJ, Moseley TW, Scoggins ME, Mahmoud HS, White JB, Hwang KP, Elshafeey NA, Boge M, Zhang S, Litton JK, Valero V, Tripathy D, Thompson AM, Yam C, Wei P, Moulder SL, Pagel MD, Yang WT, Ma J, Rauch GM. Quantitative apparent diffusion coefficients from peritumoral regions as early predictors of response to neoadjuvant systemic therapy in triple-negative breast cancer. J Magn Reson Imaging 56(6):1901-1909, 2022. e-Pub 2022. PMID: 35499264.
38. Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, Trials Group ERC. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol 23(12):1517-1524, 2022. e-Pub 2022. PMID: 36306810.
39. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Huo L, White JB, Tripathy D, Valero V, Litton JK, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. Cancer Res 82(18):3394-3404, 2022. e-Pub 2022. PMID: 35914239.
40. Huang ML, Hess K, Ma J, Santiago L, Scoggins ME, Arribas E, Adrada BE, Le-Petross HT, Leung JWT, Yang W, Geiser W, Candelaria RP. Prospective comparison of synthesized mammography with DBT and full-field digital mammography with DBT uncovers recall disagreements that may impact cancer detection. Acad Radiol 29(7):1039-1045, 2022. e-Pub 2022. PMID: 34538550.
41. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
42. Candelaria RP, Adrada BE, Lane DL, Rauch GM, Moulder SL, Thompson AM, Bassett RL, Arribas EM, Le-Petross HT, Leung JWT, Spak DA, Ravenberg EE, White JB, Valero V, Yang WT. Midtreatment ultrasound descriptors as qualitative imaging biomarkers of pathologic complete response in patients with triple negative breast cancer. Ultrasound Med Biol 48(6):1010-1018, 2022. e-Pub 2022. PMID: 35300879.
43. Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK, Adrada BE, Candelaria RP, White J, Thompson AM, Huo L, Wei P, Tripathy D, Valero V, Yam C, Hazle JD, Moulder SL, Yang WT, Rauch GM. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol 149:110220, 2022. e-Pub 2022. PMID: 35193025.
44. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic impact of high baseline stromal tumor-infiltrating lymphocytes in the absence of pathologic complete response in early-stage triple-negative breast cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267631.
45. Candelaria RP, Spak DA, Rauch GM, Huo L, Bassett RL, Santiago L, Scoggins ME, Guirguis MS, Patel MM, Whitman GJ, Moulder SL, Thompson AM, Ravenberg EE, White JB, Abuhadra NK, Valero V, Litton J, Adrada BE, Yang WT. BI-RADS ultrasound lexicon descriptors and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer. Acad Radiol 29 Suppl 1:S35-S41, 2022. e-Pub 2022. PMID: 34272161.
46. Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenberg E, Lim B, Litton J, Tripathym D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R, White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JF. Application of artificial intelligence to plasma metabolomics profiles to predict response to neoadjuvant chemotherapy in triple-negative breast cancer. Front Artif Intell 5:876100, 2022. e-Pub 2022. PMID: 36034598.
47. Adrada BE, Candelaria R, Moulder S, Thompson A, Wei P, Whitman GJ, Valero V, Litton JK, Santiago L, Scoggins ME, Moseley TW, White JB, Ravenberg EE, Yang WT, Rauch GM. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer 127(16):2880-2887, 2021. e-Pub 2021. PMID: 33878210.
48. Musall BC, Abdelhafez AH, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Le-Petross H, Arribas E, Lane DL, Spak DA, Leung JWT, Hwang KP, Son JB, Elshafeey NA, Mahmoud HS, Wei P, Sun J, Zhang S, White JB, Ravenberg EE, Litton JK, Damodaran S, Thompson AM, Moulder SL, Yang WT, Pagel MD, Rauch GM, Ma J. Functional tumor volume by fast dynamic contrast-enhanced MRI for predicting neoadjuvant systemic therapy response in triple-negative breast cancer. J Magn Reson Imaging 54(1):251-260, 2021. e-Pub 2021. PMID: 33586845.
49. Nia ES, Huang ML, Sun SX, Mitchell MP, Myatt JP, Candelaria RP. The mammographic appearance of the BioMonitor implantable loop recorder. Clin Imaging 73:28-30, 2021. e-Pub 2021. PMID: 33296770.
50. Guirguis MS, Adrada B, Santiago L, Candelaria R, Arribas E. Mimickers of breast malignancy: Imaging findings, pathologic concordance and clinical management. Insights Imaging 12(53), 2021. e-Pub 2021. PMID: 33877461.
51. Nia ES, Adrada BE, Whitman GJ, Candelaria RP, Krishnamurthy S, Bassett RL, M Arribas E. MRI features of pseudoangiomatous stromal hyperplasia with histopathological correlation. Breast J 27(3):242-247, 2021. e-Pub 2021. PMID: 33393706.
52. Bragg A, Candelaria R, Adrada B, Huang M, Rauch G, Santiago L, Scoggins M, Whitman G. Imaging of noncalcified ductal carcinoma in situ. J Clin Imaging Sci 11(34):34, 2021. e-Pub 2021. PMID: 34221643.

Review Articles

1. Huang, ML, Lane, DL, Chang Sen, LQ, Candelaria, RP, Santiago, L. Postcryoablation Breast Imaging Algorithms, Findings, and Standardized Reporting. Journal of Breast Imaging 8(1):96-108, 2026. e-Pub 2026. PMID: 41558639.
2. Huang ML, Tomkovich K, Lane DL, Katta R, Candelaria RP, Santiago L. Breast cancer cryoablation fundamentals past and present technique optimization and imaging pearls. Acad Radiol 30(10):2383-2395, 2023. e-Pub 2023. PMID: 37455177.
3. Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang WT, Rauch GM. Tumor necrosis by pretreatment breast MRI: Association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat 185(1):1-12, 2021. e-Pub 2021. PMID: 32920733.

Other Articles

1. Adrada, BE, Guirguis, MS, Huo, L, Yam, C, Tripathy, D, Candelaria, RP, Yang, W, Patel, MM, Moseley, T, Whitman, GJ, Leung, J, Le-Petross, H, Lane, DL, Abuhadra, NK, Litton, J, Valero, V, Hunt, KK, Arun, BK, Mohamed, R, Sun, J, Korkut, A, Pashapoor, S, White, JB, Thompson, A, Wei, P, Ma, J, Moulder, S, Rauch, GM Erratum Imaging- and Tumor Biomarker–Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. JCO Precis Oncol 10(5), 2026. PMID: 42150150.

Abstracts

1. Weaver OO, Guirguis MS, Moseley T, Candelaria RP, Adrada BE, Kommula N, Leung JW, Whitman GJ, Irajizad E, Dennison JB, Kapoor MM. Adding digital breast tomosynthesis may maximize the success rate of contrast-enhanced mammography-guided biopsies. EUSOBI Annual Scientific Meeting 2026, 2026. e-Pub 2026.
2. Weaver OO, Whitman GJ, Guirguis MS, Kapoor MM, Leung JW, Moseley T, Candelaria RP, Patel MM, Yang WT, Layman RR, Jacobsen M, Geiser W, Ahmad M, Dennison JB, Adrada B. The effects of inter-vendor image display variations and same-vendor dose adjustments on short-term follow-up of probably benign findings on contrast-enhanced mammography. EUSOBI Annual Scientific Meeting, 2025. e-Pub 2025.
3. Candelaria RP, Sun J, Adrada B, Guirguis M, Lane D, Le-Petross H, Leung J, Patel M, Perez F, Whitman G, Yam C, Yang WT, Rauch G. Can sentinel lymph node biopsy after neoadjuvant systemic therapy be omitted in clinically-node negative triple negative breast cancer patients?. 2024 Society of Breast Imaging Symposium, 2024. e-Pub 2024.
4. Mohamed RM, Panthi B, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, K-P H, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel M, Chen H, Sun J, Wei P, Thompson AM, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G. Multi-parametric MRI-based radiomics models from tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant systemic therapy in triple negative breast cancer patients. Cancer Res 83(5 suppl), 2023. e-Pub 2023.
5. Panthi B, Mohamed RM, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, K-P H, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel M, Chen H, Sun J, Wei P, Thompson AM, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G. Longitudinal DCE-MRI radiomic models for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. Cancer Res 83(5 suppl), 2023. e-Pub 2023.
6. Guirguis MS, Adrada B, Patel M, Perez F, Candelaria R, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross HCT, Leung J, Whitman GJ, Lane DL, Scoggins ME, Moseley T, Musall B, White J, Pashapoor S, Wei P, Son JB, K-P H, Panthi B, Pagel M, Huo L, Hunt KK, Ravenberg E, Thompson AM, Litton JK, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Rauch G. DCE-MRI for early prediction of excellent response versus chemoresistance in triple negative breast cancer. Cancer Res 83(5 suppl), 2023. e-Pub 2023.
7. Mohamed RM, Panthi B, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, K-P H, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Chen H, Sun J, Wei P, Litton JK, Valero V, Yam C, Pagel M, Ma J, Rauch G. A pre-operative dynamic contrast enhanced MRI-based radiomics models as predictors of treatment response after neoadjuvant systemic therapy in triple negative breast cancer patients. Cancer Res 83(5 suppl), 2023. e-Pub 2023.
8. Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada BE, Arun BK, Barcenas CH, Bisen A, Booser D, Buzdar A, Candelaria R, Chen J, Clayborn A, Damodaran S, Ding Q, Garber H, Hortobagyi GN, Hunt KK, Ibrahim NK, Iheme A, Karuturi MS, Koenig K, Layman RM, Lee J, Litton JK, Mitchell M, Moscol G, Mouabbi J, Murthy RK, Oke O, Pohlmann P, Ramirez D, Ravenberg E, Saleem S, Teshome M, Valero V, White J, Williams M, Woodard WA, Yajima C, Ueno NT, Chen K, Rauch G, Huo L, Tripathy D. HER2–01: Clinical and molecular characteristics of HER2–low/zero early stage triple–negative breast cancer. Cancer Res 83(5 suppl), 2023. e-Pub 2023.
9. Guirguis MS, Adrada BE, Patel M, Perez F, Candelaria RP, Yang WT, Sun J, Mohamed RMM, Boge M, Le-Petross HC, Leung JWT, Whitman GJ, Lane DL, Scoggins ME, Moseley TW, Musall B, White J, Zhou Z, Pashapoor S, Wei P, Son JB, K-P H, Panthi B, Pagel MD, Huo L, Hunt KK, Ravenberg E, Thompson A, Litton J, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Rauch GM. Early prediction of chemoresistance versus excellent response in triple negative breast cancer patients with DCE-MRI. Cancer Res 83(5 suppl), 2023. e-Pub 2023.
10. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed R, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Yam C, Son JB, Ma J, Rauch GM. Forecasting treatment response to neoadjuvant therapy in triple-negative breast cancer via an image-guided digital twin. Cancer Res 82(12 suppl), 2022. e-Pub 2022.
11. Elshafeey N, Hwang KP, Adrada BE, Candelaria RP, Boge M, Mahmoud RM, Chen H, Sun J, Yang W, Kotrotsou A, Musall BC, Son JB, Whitman GJ, Leung J, Le-Petross H, Santiago L, Lane DL, Scoggins ME, Spak DA, Guirguis MS, Patel MM, Perez F, Abdelhafez AH, White JB, Hu L, Ravenberg E, Peng W, Thompson A, Damodaran S, Tripathy D, Moulder SL, Yam C, Pagel MD, Ma J, Rauch GM. Radiomics model based on magnetic resonance image compilation (MagIC) as early predictor of pathologic complete response to neoadjuvant systemic therapy in triple-negative breast cancer. Cancer Res 82(4 suppl), 2022. e-Pub 2022.
12. Patel MM, Adrada BE, Lopez B, Candelaria RP, Sun J, Boge M, Mohamed RM, Elshafeey N, Whitman G, Le-Petross HT, Santiago L, Scoggins ME, Lane D, Moseley T, Zylberman G, Saddler J, Leung JWT, Yang WT, Valero V, Kappadath SC, Rauch GM. Quantitative molecular breast imaging for early prediction of neoadjuvant systemic therapy response in locally advanced breast cancer patients. Cancer Res 82(4 suppl), 2022. e-Pub 2022.
13. Guirguis MS, Adrada BE, Candelaria RP, Sun J, Whitman GJ, Yang WT, Boge M, Mohamed RM, Elshafeey NA, Lane DL, Le-Petross H, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel M, Perez F, Wei P, Tripathy D, White J, Ravenberg E, Huo L, Litton J, Arun B, Valero V, Thompson A, Moulder S, Yam C, Rauch GM. Prediction of response to neoadjuvant systemic therapy in triple negative breast cancer using baseline tumor MRI characteristics and imaging patterns of response. Cancer Res 82(4 suppl), 2022. e-Pub 2022.
14. Rauch GM, Candelaria RP, Guirguis MS, Boge M, Mohamed RMM, Elshafeey N, Sun J, Whitman GJ, Leung J, Le-Petross HC, Santiago L, Lane D, Scoggins M, Spak D, Patel MM, Perez F, White JB, Ravenberg E, Peng W, Tripathy D, Valero V, Litton J, Huo L, Yam C, Thompson A, Ma J, Moulder SL, Yang W, Adrada BE. Integrated model for early prediction of neoadjuvant systemic therapy response in triple negative breast cancer. Cancer Res 82(4 suppl), 2022. e-Pub 2022.
15. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed RM, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Moulder S, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Forecasting treatment response to neoadjuvant systemic therapy in triple negative breast cancer via mathematical modeling and quantitative MRI. Cancer Res 82(4 suppl), 2022. e-Pub 2022.
16. Zhou Z, Elshafeey NA, Rauch DE, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Mohamed RM, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, Tripathy D, Valero V, Yam C, Moulder S, White JB, Son JB, Pagel MD, Rauch GM, Ma J. Deep learning for early prediction of neoadjuvant chemotherapy response in triple negative breast cancers. Cancer Res 82(4 suppl), 2022. e-Pub 2022.
17. Yam C, Mittendorf EA, Sun R, Huo L, Damodaran S, Rauch GM, Candelaria RP, Adrada BE, Seth S, Symmans WF, Murthy RK, White JB, Ravenberg E, Clayborn A, Prabhakaran S, Valero V, Thompson AM, Tripathy D, Moulder SL, Litton JK. Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC). J Clin Oncol 39(15 suppl), 2021. e-Pub 2021.
18. Elshafeey N, Adrada BE, Candelaria RP, Abdelhafez AH, Musall BC, Sun J, Boge M, Mohamed RMM, Mahmoud HS, Son JB, Kotrosou A, Zhang S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, White JB, Ravenberg E, Hwang KP, Wei P, Litton JK, Huo L, Tripathy D, Valero V, Thompson AM, Moulder S, Yang WT, Pagel MD, Ma JF, Rauch GM. Radiomic phenotypes from dynamic contrast-enhanced MRI (DCE-MRI) parametric maps for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. Cancer Res 81(4 suppl), 2021. e-Pub 2021.
19. Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RMM, Yang W, Elshafeey NA, Sun J, Abdelhafez AH, Son JB, White JB, Moseley T, Whitman G, Le-Petross H, Santiago S, Lane DL, Leung JWT, Scoggins ME, Spak DA, Arribas E, Ravenberg E, Musall BC, Miyoshi M, Wang X, Willis B, Hash S, Kotrotsou A, Wei P, K-P H, Litton J, Thompson A, Moulder SL, Candelaria RP, Ma J, Pagel MD. Assessment of early response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC) using chemical exchange saturation transfer (CEST) MRI: pilot study. Cancer Res 81(4 suppl), 2021. e-Pub 2021.
20. Rauch GM, Drukker K, Elshafeey N, Mohamed RMM, Boge M, Adrada BE, Candelaria RP, Salama M, Shkatova I, Giger M, Yang WT. Quantitative dynamic contrast-enhanced (DCE) MRI radiomic phenotypes for prediction of nodal and distal metastasis in breast cancer patients. Cancer Res 81(2 suppl), 2021. e-Pub 2021.
21. Rauch GM, Beatriz AE, Candelaria RP, Elshafeey N, Abdelhafez AH, Musall BC, Sun J, Boge M, Mohamed RMM, Son JB, Zhang S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, White JB, Ravenberg E, Hwang KP, Wei P, Huo L, Litton JK, Valero V, Tripathy D, Thompson AM, Pagel MD, Ma JF, Yang WT, Moulder S. Volumetric changes on longitudinal dynamic contrast enhanced MR imaging (DCE-MRI) as an early treatment response predictor to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. Cancer Res 81(4 suppl), 2021. e-Pub 2021.